Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multicentre comparative study of two schedules of gabexate mesilate in thetreatment of acute pancreatitis
Autore:
Pezzilli, R; Miglioli, M;
Indirizzi:
St Orsola Hosp, Emergency Dept, I-40138 Bologna, Italy St Orsola Hosp Bologna Italy I-40138 rgency Dept, I-40138 Bologna, Italy St Orsola Hosp, Dept Internal Med & Gastroenterol, I-40138 Bologna, Italy St Orsola Hosp Bologna Italy I-40138 stroenterol, I-40138 Bologna, Italy
Titolo Testata:
DIGESTIVE AND LIVER DISEASE
fascicolo: 1, volume: 33, anno: 2001,
pagine: 49 - 57
SICI:
1590-8658(200101/02)33:1<49:MCSOTS>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
SERINE-PROTEASE INHIBITOR; DOUBLE-BLIND TRIAL; THERAPY; INTERLEUKIN-6; METAANALYSIS; SERUM;
Keywords:
acute pancreatitis; gabexate mesilate; Glasgow criteria;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Pezzilli, R St Orsola Hosp, Emergency Dept, Via Massarenti 9, I-40138 Bologna, Italy St Orsola Hosp Via Massarenti 9 Bologna Italy I-40138 , Italy
Citazione:
R. Pezzilli e M. Miglioli, "Multicentre comparative study of two schedules of gabexate mesilate in thetreatment of acute pancreatitis", DIG LIVER D, 33(1), 2001, pp. 49-57

Abstract

Aim. To compare the efficacy of two different schedules of gabexate mesilate (900 mg/day, or 1,500 mg/day) in the treatment of severe acute pancreatitis. Setting. Forty-two Italian medical and surgical centres took part in the study. Study design. A multicentre, prospective, open label, comparative, parallel-group, randomized study. Methods. The patients enrolled in the study had acute pancreatitis as demonstrated by typical abdominal pain and baseline serum amylase concentrations more than twice the upper normal limit, findings compatible with acute pancreatitis at imaging techniques, and a Glasgow criteria score of greater than or equal to3. Patients were randomly assigned to one of the two schedules of treatment with gabexate mesilate being administered intravenously forat least 7 days. The minimum clinically relevant difference (delta), between groups, in incidence of complications due to acute pancreatitis, during the first month of the study treatment, was predefined as equal to 10%. Results. A total of 199 patients were assigned to gabexate mesilate 900 treatment and 189 to gabexate mesilate 1,500. Complications developed in 88 patients within one month of beginning treatment 44/199: patients (22.1%) inthe gabexate mesilate 900 group and 44/489 patients (23.3%) in the gabexate mesilate 1,500 group (difference 1.2%; 95% confidence interval: -7.2, 9.5%). Conclusions. Gabexate mesilate 900 mg per day is as effective as gabexate mesilate 1500 mg per day in reducing the complications due to acute pancreatitis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 06:46:09